Mirum Pharmaceuticals Inc [MIRM] stock is trading at $89.5, up 3.38%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MIRM shares have gain 18.45% over the last week, with a monthly amount glided 38.39%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Mirum Pharmaceuticals Inc [NASDAQ: MIRM] stock has seen the most recent analyst activity on September 24, 2025, when TD Cowen initiated its Buy rating and assigned the stock a price target of $95. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $48 on April 17, 2024. H.C. Wainwright reiterated its recommendation of a Buy and reduced its price target to $58 on December 18, 2023. In a note dated November 13, 2023, Morgan Stanley initiated an Overweight rating and provided a target price of $60 on this stock.
Mirum Pharmaceuticals Inc [MIRM] stock has fluctuated between $36.88 and $86.79 over the past year. Currently, Wall Street analysts expect the stock to reach $102.9 within the next 12 months. Mirum Pharmaceuticals Inc [NASDAQ: MIRM] shares were valued at $89.5 at the most recent close of the market. An investor can expect a potential return of 14.97% based on the average MIRM price forecast.
Analyzing the MIRM fundamentals
Mirum Pharmaceuticals Inc [NASDAQ:MIRM] reported sales of 471.79M for the trailing twelve months, which represents a growth of 47.17%. Gross Profit Margin for this corporation currently stands at 0.8% with Operating Profit Margin at -0.09%, Pretax Profit Margin comes in at -0.09%, and Net Profit Margin reading is -0.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is -0.16 and Total Capital is -0.07. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Mirum Pharmaceuticals Inc’s Current Ratio is 3.31. In addition, the Quick Ratio stands at 3.16 and the Cash Ratio stands at 1.76. Considering the valuation of this stock, the price to sales ratio is 9.80, the price to book ratio is 15.73.
Transactions by insiders
Recent insider trading involved Ramasastry Saira, Director, that happened on Dec 22 ’25 when 5000.0 shares were sold. Director, GREY MICHAEL G completed a deal on Dec 19 ’25 to sell 50000.0 shares. Meanwhile, Director SAIRA RAMASASTRY bought 5000.0 shares on Dec 22 ’25.
